Gene delivery using AAV8 in vivo for disease stabilization in a bimodal gene therapy approach for the treatment of ADA-deficient SCID
Open Access
- 15 February 2021
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 20, 765-778
- https://doi.org/10.1016/j.omtm.2021.02.007
Abstract
No abstract availableFunding Information
- National Institutes of Health
- California Institute for Regenerative Medicine
This publication has 42 references indexed in Scilit:
- Recombinant Adeno-Associated Virus-Mediated Gene Transfer for the Potential Therapy of Adenosine Deaminase-Deficient Severe Combined Immune DeficiencyHuman Gene Therapy, 2011
- Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA miceHuman Molecular Genetics, 2010
- Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene TherapyMolecular Therapy, 2010
- How I treat ADA deficiencyBlood, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansionBlood, 2008
- In Vivo Transduction by Intravenous Injection of a Lentiviral Vector Expressing Human ADA into Neonatal ADA Gene Knockout Mice: A Novel Form of Enzyme Replacement Therapy for ADA DeficiencyMolecular Therapy, 2006
- Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined ImmunodeficiencyOnline Journal of Public Health Informatics, 1998
- PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 yearsClinical Immunology and Immunopathology, 1995
- Severe Combined Immunodeficiency of Reduced Severity Due to Homozygosity for an Adenosine Deaminase Missense Mutation (ARG253PRO)Cellular Immunology, 1993